Sendai Viral Vector for iPS Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPS cells) from human peripheral blood monocytes face challenges in ensuring genetic information identity with the patient, avoiding immunological rejection, and minimizing the risk of tumorigenesis due to foreign gene insertion, while also requiring non-invasive collection methods and low contamination risks.
Innovation Solution
A method using a Sendai viral vector loaded with reprogramming genes Oct3/4, Sox2, and Klf4 for sustained expression in monocytes, which can be easily removed post-reprogramming using siRNA, ensuring the iPS cells have genetic information identical to the patient and avoiding chromosomal integration of foreign genes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If retroviral or lentiviral vectors are used to transfect reprogramming genes into monocytes, then iPS cells can be generated, but foreign genes integrate into chromosomes causing tumorigenesis risk
Solution Approach 1:
The patent extracts and removes the problematic integrating capability from the viral vector system. By using Sendai virus which replicates in the cytoplasm without integrating into host chromosomes, the invention separates the gene delivery function from the harmful integration function, thereby eliminating tumorigenesis risk while maintaining reprogramming efficiency
Solution Approach 2:
The Sendai virus acts as an intermediary that temporarily delivers reprogramming genes into monocytes without permanently integrating. The virus serves as a transient mediator that can be completely removed after gene delivery, unlike retroviral vectors that permanently integrate foreign DNA into the host genome
2Ease of manufacture
If skin-derived fibroblast cells are used as raw material for h iPS cells, then reprogramming can be achieved, but invasive collection methods are required
Solution Approach 1:
Instead of using traditionally invasive sources like skin fibroblasts, the patent inverts the approach by using peripheral blood monocytes which can be collected through simple blood draw. This reverses the conventional wisdom that solid tissue biopsies are necessary for reprogramming, demonstrating that easily accessible blood cells are superior starting materials
3Reliability
If foreign genes are introduced into monocytes for reprogramming, then h iPS cells can be generated, but immunological rejection may occur
Solution Approach 1:
The patent extracts foreign genes completely from the final iPS cell product. By using Sendai virus that does not integrate and can be fully removed, the invention ensures the final cells contain only the patient's own genetic material, eliminating the risk of immunological rejection from foreign gene presence
Solution Approach 2:
The patent performs preliminary removal of the Sendai virus vector during the reprogramming process itself, rather than requiring post-reprogramming cleanup. This preliminary action ensures foreign genes are eliminated before the iPS cells are used for therapy, guaranteeing genetic purity
4Productivity
If Sendai viral vector is used for sustained gene expression, then reprogramming efficiency increases, but vector removal is required
Solution Approach 1:
The patent employs self-service mechanisms for vector removal through two approaches: (1) The temperature-sensitive L protein allows spontaneous virus inactivation and removal by simply changing cultivation temperature to non-permissive conditions, and (2) siRNA automatically degrades remaining viral RNA. These self-service mechanisms eliminate complex manual purification steps
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for the efficient and safe production of iPS cells with complete genetic identity, reducing the risk of immunological rejection and tumorigenesis, and can be performed with minimal invasion and low contamination risk, making it suitable for regenerative therapies.
Implementation Method 1
infecting a peripheral blood-derived mononuclear cell with a reprogramming gene-loaded Sendai virus vector to reprogram the mononuclear cell
Implementation Method 2
the L protein expressed by the L gene of the reprogramming gene-loaded Sendai virus vector has a valine as an amino acid residue at position 1618 that enables sustained gene expression
Implementation Method 3
the reprogramming gene-loaded Sendai virus vector can be easily removed from the cell using siRNA that targets a preselected sequence that is incorporated into the Sendai virus genome
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Induced pluripotent stem cells having genetic information identical to that of a patient and yet having nature close to those of ES cells are prepared from human peripheral blood monocytes without leaving those genes in the resultant cells after use for their preparation. Reprogramming genes are loaded on sustained expression-inducing Sendai viral vectors which do not have an activity for integrating foreign genetic information into chromosomes and they are introduced into peripheral blood-derived monocytes to be expressed. Subsequently, the vector genome RNA comprising the reprogramming genes is removed from the cells to establish induced pluripotent stem cells. The above-described Sendai viral vector is capable of extremely simple and efficient preparation of induced pluripotent stem cells having genetic information identical to that of an individual who supplied the differentiated cell and yet this vector is safe presenting only a low risk of tumorigenesis. By supplying useful induced pluripotent stem cells, this Sendai viral vector can serve as a powerful tool in various applications including safe and efficient performance of cell replacement therapy.